News

December 6, 2012 — Daiichi Sankyo Inc. and Eli Lilly and Co. announced results of two retrospective studies comparing rates of readmission for subsequent heart attack and initial hospitalization...

Clopidogrel Prasugrel TCT 2012 Smoking PARADOX Study Antiplatelet Therapy

Results of a study investigating the effects of smoking on the antiplatelet medications clopidogrel and prasugrel were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT)...

A large observational study found the increased risk associated with dual antiplatelet therapy cessation after percutaneous coronary intervention (PCI) is tied to patient non-adherence, as opposed...

November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the...

November 9, 2012 — Bristol-Myers Squibb Co. and Pfizer Inc. announced that the reductions in stroke or systemic embolism, major bleeding, and mortality demonstrated with Eliquis compared to...

Xarelto rivaroxaban Janssen Pharmaceuticals Deep Vein Thromosis Treament

Janssen Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), an oral anticoagulant, for the...

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according to measured platelet reactivity is superior to prasugrel therapy in...

October 2, 2012 — AstraZeneca has announced the results from a sub-analysis of PLATO that evaluated the effects of age on clinical outcomes in patients with acute coronary syndrome (ACS). Results...

October 2, 2012 — A novel blood thinner recently approved by the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), has been rapidly adopted into clinical practice, yet thus far has...

Pfizer Bristol-Myers Squibb Eliquis

October 1, 2012 — Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the new drug application (NDA) resubmission...

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-...

September 25, 2012 — Patients are often aggressively treated with anticoagulants, or blood thinners, to help prevent...

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

September 13, 2012 — Janssen Research & Development LLC announced that it has submitted the complete response to the U.S. Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in...

August 30, 2012 — Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination...

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents —...